Multifunctional Platform for Viscoelastic aPTT and Fluorometric aFXa Whole Blood Testing in Near-Patient Settings for Pediatric Patients on Heparin Therapy Heparin monitoring tests for anti-Factor Xa activity (aFXa) and activated …
Near-Patient Digital Microfluidics G6PD Assay
Preliminary Investigation into the Prevalence of G6PD Deficiency in a Pediatric African American Population using a Near-Patient Diagnostic Platform In this study, a near-patient digital microfluidics (DMF) glucose-6-phosphate dehydrogenase (G6PD) …
Cytomegalovirus PCR from Saliva in Minutes
Using a Digital Microfluidics Disposable Cartridge in a Near-Patient Platform This study demonstrates feasibility of CMV PCR assays from newborn saliva in a digital microfluidics (DMF) disposable cartridge to enable …
The first experience in Tuscany
Digital microfluidics (DMF), a new technology for newborn screening of Lysosomal Storage Disease A comparative study was performed in Florence Italy between our SEEKER digital microfluidics (DMF) platform and the …
Reducing False Positives in Newborn Screening for Lysosomal Storage Disorders
NBS programs should consider optimized first-tier cutoffs and integration of second-tier targeted next generation sequencing in screening for lysosomal storage disorders to reduce false positives and provide customizable patient referral. See poster from WORLDSymposium 2020.
Comprehensive, Near Patient Hyperbilirubinemia Testing in Newborns Using Low Blood Volume
Neonatal jaundice is a common condition that can lead to severe hyperbilirubinemia and kernicterus if not treated promptly. Comprehensive determination of hyperbilirubinemia risk requires testing for multiple analytes, including total serum bilirubin (TSB), albumin and glucose-6-phosphate dehydrogenase (G6PD), which currently are performed separately.
Comparison of Newborn Screening Platforms for Lysosomal Storage Disorders
As newborn screening (NBS) programs expand to include lysosomal storage disorders (LSDs), prospective results from active LSD screening programs can be used to compare the performance of available screening methodologies. Two FDA-cleared platforms are currently available for LSD enzyme testing from dried blood spot specimens – tandem mass spectrometry (MS/MS) and digital microfluidic fluorometry (DMF). The emerging clinical results reflect the real world performance of each platform and should be considered alongside the associated costs (equipment, maintenance, personnel, etc.) and workflow of each platform to determine the best fit for each NBS laboratory.
Development of a Creatine Kinase Assay Coupled with Targeted NGS to Screen Newborns and Infants for DMD & Congenital Muscular
Early diagnosis of Duchenne Muscular Dystrophy (DMD) and other congenital muscular dystrophies (CMD) is essential for preventing permanent muscle damage. View poster from Muscular Dystrophy Association 2019 Clinical and Scientific Conference 2019.
Versatility of Digital Microfluidics for Screening and Clinical Testing in Newborns
To aid in the ongoing expansion of newborn screening, our team has applied digital microfluidics technology to automate a broad range of clinical assays onto disposable cartridges using nanoliter droplets of sample and reagents. See Baebies poster from APHL NBSGTS 2019.
A Qualitative, Multiplexed Real-Time PCR Screen for Rapid Detection of cCMV Enabling Timely Intervention
Congenital cytomegalovirus (cCMV) infection in newborns can lead to permanent hearing loss and developmental delays if left untreated. Baebies’ Qualitative PCR Assay for cCMV was developed and validated in-house to provide timely and accurate identification of infected babies, facilitating early intervention.
- Page 1 of 2